Although it has been documented that celecoxib19, 21 or celecoxib-loaded nanoparticles22 could be utilized to suppress tumor growth or metastasis by inhibition of the COX-2-related signaling pathway, there have been very few studies using COX-2 inhibitors to regulate the tumor microenvironment and help increase the delivery of nanotherapeutics for tumors. This evidence concerns the gene PTGS2 and neoplasm.